Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

PARP Inhibitor Biomarkers Market – Market Insights

PARP are poly(adenosine diphosphate [ADP] -ribose) polymerase. It is a group of 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. Poly(ADP-ribose) polymerase (PARP) inhibitor plays a vital role in the repair of single-strand DNA. PARP inhibitors are thought to become trapped at the sites of single-strand DNA breaks leading to double-strand DNA breaks when DNA replication is attempted. The double-strand DNA breaks would normally be repaired by the process of homologous recombination repair (HRR), which is a complex process including many proteins, notably BRCA1 and BRCA2 which are also known as biomarkers of PARP inhibitors.

The global PARP inhibitor biomarkers market was valued at US$ 374.9 Mn in 2019, and is expected to exhibit a CAGR of 24.5% during the forecast period (2019–2027).

Figure 1. Global PARP Inhibitor Biomarkers Market Value (US$ Mn), by Region, 2019

PARP Inhibitor Biomarkers  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

The increasing prevalence of cancer globally is expected to drive growth of the global PARP inhibitor biomarkers market during the forecast period

Cancer is a class of chronic diseases characterized by out-of-control growth of cells. According to the National Cancer Institute report published in 2013 stated that there are over 100 different types of cancers that can be described from the type of cells they are formed from.

According to the World Health Organization’s 2018 report, cancer is the second leading cause of morbidity and mortality worldwide and was responsible for an estimated 9.6 million deaths in 2018. According to the same source, globally, around 1 in 6 deaths occur due to cancer.

 According to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., which accounted for around 1 out of every 4 deaths in the U.S.

Moreover, increasing incidence of breast and ovarian cancer is expected to drive the market growth during the forecast period. For instance, according to the World Cancer Research Fund International’s report of 2018, breast cancer was at the second position among the total number of cancer cases worldwide, accounting for 2,088,849 new cases in 2018.

According to American Cancer Society, in 2018, an estimated 266,120 new cases of invasive breast cancer were diagnosed among women in the U.S.

However, high cost of PARP inhibitor biomarker test kits and assays is expected to hamper the growth of the global PARP inhibitor biomarkers market. For instance, in October 2019, Myriad Genetics, Inc.’s myChoice CDx became commercially available with a list price of US$ 4,040. myChoice CDx is the first and only FDA-approved tumor test that determines homologous recombination deficiency status by detecting BRCA1 and BRCA2.

Figure 2. Global PARP Inhibitor Biomarkers Market Share (%), by Application

PARP Inhibitor Biomarkers  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

An increasing number of product approvals is expected to drive the market growth during the forecast period

Untapped markets in emerging economies can be capitalized through favorable product pricing and new product approvals, which can further facilitate use of PARP inhibitors biomarkers.

For instance, in May 2019, AstraZaneca and Merck received the Health Canada approval for Lynparza as a monotherapy maintenance treatment for adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer

Similarly, in April 2018, Myriad Genetic Laboratories, Inc., a subsidiary of Myriad Genetics, Inc., received manufacturing and marketing approval for Myriad's BRACAnalysis Diagnostic System from the Japanese Ministry of Health, Labour, and Welfare to be used as a companion diagnostic with the PARP inhibitor, Lynparza

Key Players

Major players operating in the global PARP inhibitor biomarkers market include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc.

PARP inhibitors are drugs which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitor biomarker are developed for diagnosis and treatment of several diseases, and the most important one is cancer. Several types of cancers rely on PARP enzymes than regular cells which make these inhibitors an effective mode for treating cancers. PARP inhibitors are used to treat a subset of ovarian and breast cancer. There are several testing services for PARP inhibitors biomarkers which include BRCA 1 & 2 testing, HRD testing, HRR testing, and others.

Market Dynamics

Research and development of novel therapies are expected to drive the global PARP inhibitor biomarkers market during the forecast period. For instance, in June 2019, researchers at the University of Montreal Hospital Research Centre (CRCHUM) developed a two-step combination therapy for the treatment of ovarian cancer. According to the research, the combination of chemotherapy and PARP inhibitors can assist in reducing the proliferation of cancer cells and destroy them. Therefore, increasing research and development in cancer treatment is expected to offer lucrative opportunities for manufacturers to commercialize new products in the market.

Key features of the study:

  • This report provides in-depth analysis of the global PARP inhibitor biomarkers market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global PARP inhibitor biomarkers market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global PARP inhibitor biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor biomarkers market

Detailed Segmentation:

  • Global PARP Inhibitor Biomarkers Market, By Product & Services:
    • Product Type
      • Kits
      • Assays
    • Services
      • BRCA 1 & 2 Testing
      • HRD Testing
      • HRR Testing
      • Others
  • Global PARP inhibitor Market, By Application:
    • Breast Cancer
    • Ovarian Cancer
    • Others (Prostate, Pancreatic, etc.)
  • Global PARP inhibitor Market, By Region:
    • North America
      • By Product & Services:
        • Product Type
          • Kits
          • Assays
        • Services
          • BRCA 1 & 2 Testing
          • HRD Testing
          • HRR Testing
          • Others
      • By Application:
        • Breast Cancer
        • Ovarian Cancer
        • Others (Prostate, Pancreatic, etc.)
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product & Services:
        • Product Type
          • Kits
          • Assays
        • Services
          • BRCA 1 & 2 Testing
          • HRD Testing
          • HRR Testing
          • Others
      • By Application:
        • Breast Cancer
        • Ovarian Cancer
        • Others (Prostate, Pancreatic, etc.)
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product & Services:
        • Product Type
          • Kits
          • Assays
        • Services
          • BRCA 1 & 2 Testing
          • HRD Testing
          • HRR Testing
          • Others
      • By Application:
        • Breast Cancer
        • Ovarian Cancer
        • Others (Prostate, Pancreatic, etc.)
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product & Services:
        • Product Type
          • Kits
          • Assays
        • Services
          • BRCA 1 & 2 Testing
          • HRD Testing
          • HRR Testing
          • Others
      • By Application:
        • Breast Cancer
        • Ovarian Cancer
        • Others (Prostate, Pancreatic, etc.)
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product & Services:
        • Product Type
          • Kits
          • Assays
        • Services
          • BRCA 1 & 2 Testing
          • HRD Testing
          • HRR Testing
          • Others
      • By Application:
        • Breast Cancer
        • Ovarian Cancer
        • Others (Prostate, Pancreatic, etc.)
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product & Services:
        • Product Type
          • Kits
          • Assays
        • Services
          • BRCA 1 & 2 Testing
          • HRD Testing
          • HRR Testing
          • Others
      • By Application:
        • Breast Cancer
        • Ovarian Cancer
        • Others (Prostate, Pancreatic, etc.)
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Myriad Genetics, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
    • Hoffmann-La Roche AG
    • Invitae Corporation
    • NeoGenomics Laboratories, Inc.
    • BPS Bioscience, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product & Services
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Mergers and Acquisitions
    • PEST Analysis
    • HRD Profiling
    • Product Mapping
    • Recent Developments
    • Epidemiology
    • Regulatory Scenario
    • Comparative Analysis of Biomarkers, by Type
    • HRR Testing Potentials
    • HRR Related Genes and Lifetime Risk of Cancers
    • Trials Combining PARP Inhibitors With Immune Checkpoint Inhibitors
    • Impact of HRR Testing On BRCA Market
  4. Global PARP Inhibitor Biomarkers Market, By Product & Services, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Product Type
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Kits
        • Assays
    • Services
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • BRCA 1 & 2 Testing
        • HRD Testing
        • HRR Testing
        • Others
  5. Global PARP Inhibitor Biomarkers Market, By Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ovarian Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others (Prostate, Pancreatic, etc.)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global PARP Inhibitor Biomarkers Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Myriad Genetics, Inc.*
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Invitae Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • NeoGenomics Laboratories, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BPS Bioscience, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 27 market data tables and 26 figures on "PARP Inhibitor Biomarkers Market” - Global forecast to 2027.

Frequently Asked Questions

This report provides in-depth analysis of the global PARP inhibitor biomarkers market and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2019 – 2027). The report also provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
Key segments covered in the report include: o Product & Services o Application o Region
The report also provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
The increasing prevalence of cancer globally, government initiatives to increase awareness about cancer treatment and an increasing number of product approvals are likely to facilitate the market growth.
The report profiles leading players in the global PARP inhibitor biomarkers market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner